Tonight is creating a lively – and for some lucrative – afternoon session for night traders. There are some interesting news to digest, and at least a few stocks on the go as a result.
Which companies are these? Read on to find out.
Image Source: Getty Images.
Illumina cuts her full-year tutorial
<p class = "canvas-atom canvas text Mb (1.0em) Mb Illumina (NASDAQ: ILMN) really takes it on the hook (0) – sm Mt (0.8em) – sm "type =" text "content = Tonight, after the market reached, the company was aware that quarterly revenue was not expected. It also chopped its top line for the 2019 budget. "data-reactid =" 26 "> Shares of DNA sequencing company Illumina (NASDAQ: ILMN) really takes it on the chin tonight. After the market was close, the company was aware that quarterly revenue Illumina said its preliminary figures indicate that it will order $ 835 million for the second quarter, a $ 50 million shake from expectations, but still higher than $ 830 million in Q2, for the entire fiscal year 2019, the company believes that The top line will land 6% higher than the 2018 result of NOK 3.3 billion, previously expected a growth of 13% to 14%.
In the press release that gives the unhappy news, Illumina said the lower result than expected in 2. Quarterly, mainly due to sales that did not go through as expected in the population genomics segment, it also pointed to "ongoing weakness" with, among other things, its direct-to-consumer (DTC) work.
The company sought to retrieve a optimistic note despite the downturn, and wrote that "our preliminary analysis suggests that these challenges are temporary and do not reflect a macro change on the basis of our business. "
It doesn't look like investors are taking the company on their word. Illumina's stock is down by 16% tonight from the closing price.
<p class =" lerret-kano tekst tekst Mb (1.0em) Mb (0 ) – sm Mt (0.8em) – sm "type =" text "content =" The schedule for this announcement is not ideal for the shares. It had recently traded at its highest time, on the back of positive basics and expected advances in its ongoing acquisition of Pacific Biosciences . & Nbsp; "data-reactid =" 31 "> The timing of this announcement is not ideal for the shares, it had recently traded on its all-time high, on the back of positive basic and expected progress in its ongoing acquisition of Pacific Biosciences
Colgate-Palmolives $ 1.7 billion purchase
<p class = "canvas atomic text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "Consumer goods giant Colgate-Palmolive (NYSE: CL) will soon become a major asset. The company announced that it has entered into an agreement to purchase the skin care business of France's laboratories Filorga Cosmetiques. "Data-reactid =" 33 "> consumables giant Colgate-Palmolive (NYSE: CL) will soon be a The company announced that it has entered into an agreement to purchase the skin care business of French laboratories Filorga Cosmetiques
Colgate-Palmolive will pay $ 1.5 billion for the business, which will finance this through a combination of cash and debt. 19659018] Filorga creates a series of high-quality anti-aging skin care products, with a global presence, particularly strong in European countries such as its French France and Italy, which is also prominent in China.
The acquisition is part of Colgate-Palmolive's efforts to strengthen its presence on relatively high margin segments such as pet nutrition and personal care.
"We are pleased that this acquisition will add a high growth, profitable, global skin care activity to the Colgate portfolio with the ability to continue to grow through expanded distribution and awareness, "Colgate said in the press release."
The Filorga acquisition is subject to approval from relevant regulatory bodies. Colgate-Palmolive expects it to close in the third quarter. The company said it probably wouldn't have any impact on fiscal policy 2019.
<p class = "canvas-atom canvas text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "Text" content = "There may not have much influence on the investor's feelings, either (across some good results this has been largely positive this year.) In the aftermarket action, Colgate-Palmolive's stock is down, but only marginally. "data-reactid =" 39 "> It may not have much influence on the investor's feelings, either (because of some good results this has largely been positive this year).
New CEO of Accenture
<p class = "canvas-textile-textile Mb (1.0em) Mb (1) 0) – sm Mt (0.8em) – sm" type = " text "content =" Accenture (NYSE: ACN) announced after the market today that it has chosen a new leader. "
Accenture (NYSE: ACN) announced by market today it has chosen a new leader.
The large consulting service beats the insider company Julie Sweet to be its new CEO, replacing temporary CEO David Rowland. Sweet will begin her performance on September 1, after which she will also sit on the board. Rowland will become CEO at that time.
Sweet has been with Accenture since 2010. Today, she is CEO of the company's North America division, the most important region. Previously, she served as the company's general secretary, superior manager and secretary.
<p class = "canvas-atom canvas text Mb (1.0em) Mb (0) – sm Mt (0.8em) – Accenture's North American operations yielded 9% sales growth in the last reported quarter, and peaked The numbers of other key regions, while the company as a whole has provided encouraging improvements to both the top and bottom line recently. & nbsp; "data-reactid =" 48 "> The company's veteran seems to be a solid choice to fill the CEO's place. Accenture's operations in North America showed an increase in revenue of 9% in the last quarter reported, peaking for other key regions. Meanwhile, the company as a whole has delivered encouraging improvements on both the top and bottom line recently.
Accenture's share is a little up in the post-trade this evening.
<p class = "canvas fabric canvas text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm More from The Motley Fool " data response = "50"> More from The Motley Fool
<p class = "canvas-atom canvas- text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = " Eric Volkman has no position in any of the aforementioned shares, and Fool owns and recommends Illumina. Motley Fool is short share of Colgate-Palmolive. Motley Fool recommends Accenture. Motley Fool has a disclosure policy . "data-response time =" 58 "> Eric Volkman has no position in any of the aforementioned shares. The Motley Fool owns shares and recommends Illumina. Motley Fool is short share of Colgate-Palmolive. Motley Fool recommends Accenture. Motley Fool has a disclosure policy.